MRSH

Marsh · NYSE

News

4 latest

The Motley Fool

Marsh & McLennan: 3 Key Takeaways for Long-Term Investors

Marsh & McLennan reported 8% revenue growth in Q3 2026 and expanded its Thrive cost-efficiency program target to $600 million in savings. The company deployed digital workflows that reduced placement processing times from 2-4 weeks to hours, with 93% of London wholesale trading now digital. Management maintains a disciplined M&A strategy focused on regional bolt-on deals while continuing share buybacks and expecting margin expansion for the full year.

Zacks Investment Research

Marsh Q3 Earnings Beat Estimates on Consulting Growth Despite Higher Costs

Marsh & McLennan Companies reported Q3 2026 adjusted EPS of $2.03, beating consensus estimates by 3.6% with 9.7% year-over-year growth. Revenues climbed 8% to $6.9 billion, driven by strong consulting growth of 9% to $2.7 billion, particularly from Marsh Management Consulting which grew 14%. However, operating expenses rose 9% to $5.6 billion due to increased compensation and operating costs, limiting operating income growth to 6.1%.

Zacks Investment Research

Marsh (MRSH) Q3 Earnings and Revenues Beat Estimates

Marsh reported Q3 2026 earnings of $2.03 per share, beating consensus estimates of $1.96, with revenues of $6.86 billion exceeding expectations. However, Marsh shares have underperformed the S&P 500 by 16.6% year-to-date.

Zacks Investment Research

Marsh (MRSH) Earnings Expected to Grow: Should You Buy?

Marsh (MRSH) is anticipated to deliver year-over-year earnings growth with higher revenues for Q3 2026. The company shows a positive Earnings ESP of +0.42% combined with a Zacks Rank #3, suggesting a likely earnings beat. Marsh has a strong track record of beating consensus estimates in recent quarters.

Headlines link to the publisher. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.